Circulating DICAM as a predictor of mortality in critically ill patients with acute kidney injury requiring continuous kidney replacement therapy
Nephron · 2026-11-05
DOI: 10.1159/nef/adtag014 ↗Abstract
Abstract Introduction: Acute kidney injury (AKI) is common in critically ill patients and is associated with high mortality, highlighting the need for reliable prognostic markers. This study evaluated dual immunoglobulin domain-containing cell adhesion molecule (DICAM), an inflammation-associated transmembrane protein, as a predictor of mortality in patients with AKI requiring continuous kidney replacement therapy (CKRT). Methods: In this prospective multicenter cohort study, critically ill patients with AKI requiring CKRT were enrolled. Blood samples were obtained before CKRT initiation, and DICAM levels were measured in 115 patients. The primary outcome was in-hospital mortality. Associations between DICAM levels and mortality were assessed using Cox proportional hazards models, with DICAM analyzed as categorical and continuous variables. Results: A total of 115 patients were included in the analysis. During hospitalization, 54 patients (47.0%) died. The mean age was 65.7 ± 14.8 years, and 88 patients (76.5%) were male. The median DICAM level was 13.8 ng/mL (interquartile range [IQR], 6.9–33.5), compared with 5.9 ng/mL (IQR, 5.0–6.9) in healthy controls. When analyzed as a categorical variable (high vs. low DICAM), higher DICAM levels were associated with increased in-hospital mortality (adjusted hazard ratio [aHR], 2.05; 95% confidence interval [CI], 1.11–3.76; P = 0.021). When analyzed as a continuous variable (per 1 ng/mL increase), DICAM remained independently associated with mortality (aHR, 1.015; 95% CI, 1.005–1.025; P = 0.001). DICAM showed higher discriminatory performance for in-hospital mortality (AUC, 0.729) than APACHE II score (0.557), SOFA score (0.580), albumin (0.559), NGAL (0.595), and GDF-15 (0.554) (all P < 0.05). DICAM levels were positively correlated with SOFA score (r = 0.216, P = 0.021), NGAL (r = 0.321, P < 0.001), GDF-15 (r = 0.284, P = 0.002), and lactate (r = 0.283, P = 0.026). Conclusion: Elevated circulating DICAM levels are independently associated with increased in-hospital mortality in critically ill patients with AKI requiring CKRT. DICAM may serve as a novel prognostic biomarker in this population. Further studies are needed to validate these findings and clarify underlying mechanisms.
EUVIMED